Literature DB >> 35980230

Surface-modified nanotherapeutics targeting atherosclerosis.

Wenpan Li1, Karina Marie Gonzalez1, Jinha Chung1, Minhyeok Kim1, Jianqin Lu1,2,3,4.   

Abstract

Atherosclerosis is a chronic and metabolic-related disease that is a serious threat to human health. Currently available diagnostic and therapeutic measures for atherosclerosis lack adequate efficiency which requires promising alternative approaches. Nanotechnology-based nano-delivery systems allow for new perspectives for atherosclerosis therapy. Surface-modified nanoparticles could achieve highly effective therapeutic effects by binding to specific receptors that are abnormally overexpressed in atherosclerosis, with less adverse effects on non-target tissues. The main purpose of this review is to summarize the research progress and design ideas to target atherosclerosis using a variety of ligand-modified nanoparticle systems, discuss the shortcomings of current vector design, and look at future development directions. We hope that this review will provide novel research strategies for the design and development of nanotherapeutics targeting atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35980230      PMCID: PMC9529904          DOI: 10.1039/d2bm00660j

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   7.590


  148 in total

Review 1.  Antioxidants, statins, and atherosclerosis.

Authors:  Antonio M Gotto
Journal:  J Am Coll Cardiol       Date:  2003-04-02       Impact factor: 24.094

Review 2.  Macrophage activation by endogenous danger signals.

Authors:  X Zhang; D M Mosser
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 3.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.

Authors:  Seyed Mohammadali Dadfar; Karolin Roemhild; Natascha I Drude; Saskia von Stillfried; Ruth Knüchel; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2019-01-11       Impact factor: 15.470

4.  Arachidonic acid-modified lovastatin discoidal reconstituted high density lipoprotein markedly decreases the drug leakage during the remodeling behaviors induced by lecithin cholesterol acyltransferase.

Authors:  Hongliang He; Lisha Liu; Hui Bai; Ji Wang; Yan Zhang; Wenli Zhang; Mengyuan Zhang; Zimei Wu; Jianping Liu
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

Review 5.  Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis.

Authors:  Daniel R Lewis; Kubra Kamisoglu; Adam W York; Prabhas V Moghe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-04-26

Review 6.  The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.

Authors:  Attilio Rigotti; Helena E Miettinen; Monty Krieger
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

7.  The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.

Authors:  Jianqin Lu; Chuang Liu; Pengcheng Wang; Mohammed Ghazwani; Jieni Xu; Yixian Huang; Xiaochao Ma; Peijun Zhang; Song Li
Journal:  Biomaterials       Date:  2015-05-31       Impact factor: 12.479

8.  The role of blood flow in determining the sites of atherosclerotic plaques.

Authors:  Christina M Warboys; Narges Amini; Amalia de Luca; Paul C Evans
Journal:  F1000 Med Rep       Date:  2011-03-01

Review 9.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.